Using Immunoscore® to Assess Recurrence Risk in Nonmetastatic Colorectal Cancer Patients
Official title: Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer : Prospective Cohort Comparing the Recommandation for Patient Care According to the Immunoscore® With the Standard Care Decision.
Run by Hospital St. Joseph, Marseille, France · NCT04938986 · Data updated 2026-11-12
This study is testing if the Immunoscore® can help doctors predict the chance of cancer coming back in adults aged 18 to 80 who have had surgery for early-stage colorectal cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Hospital St. Joseph, Marseille, France Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Marseille and 1 other locations) |
| Status | Recruiting |
| Started | April 4, 2022 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | April 13, 2022 |
| Trial ID | NCT04938986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with histologically confirmed nonmetastatic colon adenocarcinoma who have undergone curative surgery.
✕Probably not a fit
Patients with a history of other solid tumors within the last three years or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of the Immunoscore® as a post-operative tool to detect the risk of recurrence in patients with nonmetastatic colorectal cancer. It focuses on patients aged 18 to 80 who have undergone curative resection for stage I, II, or III colon adenocarcinoma. The study aims to analyze how the Immunoscore® results can influence patient care recommendations and treatment decisions. Participants will provide tumor samples for research purposes and must consent to the study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans and improved outcomes for colorectal cancer patients.
How similar studies have gone: While the Immunoscore® is a novel approach, similar studies have shown promise in improving risk assessment for cancer recurrence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 18 and 80 inclusive; * histologically confirmed colon adenocarcinoma; * having undergone a curative resection of stage I, II or III colorectal cancer; * diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2; * eligible to receive 6 months of adjuvant chemotherapy; * having given free, informed and written consent; * agreeing to the use of a tumor sample for research purposes; * being affiliated to a social security system. Exclusion Criteria: * pregnant or breastfeeding women * legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study. * history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled * person subject to a safeguard measure.
Where it's running
-
Hopital Saint Joseph
Marseille, France Recruiting -
Hôpital Européen
Marseille, France Not yet recruiting
Study contacts
- Principal investigator: Hervé PERRIER, M.D — Hopital Saint Joseph Marseille
- Study coordinator: Cécile BIELMANN
- Email: cbielmann@hopital-saint-joseph.fr
- Phone: 04 88 73 10 70
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring tumor DNA methylation after surgery for colorectal cancer
This study is testing if checking for tumor DNA in the blood after surgery can help doctors better monitor recovery and spot any signs of colorectal cancer coming back in patients who are at high risk.
-
Tiered Palliative Care for Patients with Advanced Heart Failure or Cancer
This trial tests a home-based, tiered palliative care program to see if more personalized support improves symptoms and quality of life for adults with advanced heart failure or certain advanced cancers.
-
Palliative care for patients with advanced heart failure or cancer
This study is testing a new palliative care program for people with advanced heart failure or cancer to see if it can improve their quality of life and reduce hospital visits compared to standard care.
-
Botensilimab and balstilimab plus SBRT for liver‑metastatic colorectal cancer
This tests whether adding two immune drugs, botensilimab and balstilimab, to focused liver radiation (SBRT) can help people with chemorefractory, non‑MSI‑high colorectal cancer that has spread to the liver.
-
Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer
This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.